USPSTF

The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.

In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.

The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.

The group is proposing women ages 30 to 65 be screened with cervical cytology every three years or receive testing for high-risk HPV every five years.

Two researchers, who have both received grants from Epigenomics, noted in a JAMA letter that the USPSTF did not use data on the FDA-approved version of the test.

At HudsonAlpha's Genomic Medicine Conference University of North Carolina's Anya Prince discussed insurance coverage of genetic tests and preventive care.

The company said it completed about 54,000 Cologuard tests in Q2, and that the cumulative number of physicians ordering the test since its launch has risen to 41,000.

The GenomeWeb Index fell half a percent in June, underperforming the Dow Jones Industrial Average, but far outpacing the Nasdaq and Nasdaq Biotech Index.

However, the task force stopped short of recommending the use of Cologuard or other molecular assays over a variety of well-established non-molecular testing methods.

Researchers are hoping the 100,000-patient WISDOM study will lead to genetically informed breast cancer screening based on a woman's unique risk factors.

Pages

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.